XML 60 R44.htm IDEA: XBRL DOCUMENT

SEGMENT INFORMATION (Tables)

12 Months Ended

Dec. 31, 2025

Revenue	Americas	Rest of World Ireland	Eliminations	Total
Year ended December 31, 2025	US$‘000	US$‘000	US$‘000	US$‘000
Revenue from external customers	32,390	11,395	-	43,785
Inter-segment revenue	19,586	3,606	(23,192)	-

Total revenue	51,976	15,001	(23,192)	43,785

Revenue	Americas	Rest of World Ireland	Eliminations	Total
Year ended December 31, 2024	US$‘000	US$‘000	US$‘000	US$‘000
Revenue from external customers	41,792	19,763	-	61,555
Inter-segment revenue	19,815	702	(20,517)	-

Total revenue	61,607	20,465	(20,517)	61,555

Revenue	Americas	Rest of World Ireland	Eliminations	Total
Year ended December 31, 2023	US$‘000	US$‘000	US$‘000	US$‘000
Revenue from external customers	44,984	11,848	-	56,832
Inter-segment revenue	21,867	872	(22,739)	-

Total revenue	66,851	12,720	(22,739)	56,832

Revenue from customers in Ireland is not disclosed separately due to the immateriality of these revenues.

	December 31, 2025	December 31, 2024	December 31, 2023
Revenue	US$‘000	US$‘000	US$‘000
Clinical laboratory goods	31,678	39,372	42,288
Clinical laboratory services	4,006	4,750	5,453
Point-of-care	8,101	17,433	9,091

	43,785	61,555	56,832

	December 31, 2025	December 31, 2024	December 31, 2023
Revenue	US$‘000	US$‘000	US$‘000
Revenue from contracts with customers	43,785	61,555	56,832

	43,785	61,555	56,832

		Rest of World
Timing of revenue recognition	Americas	Ireland	Total
Year ended December 31, 2025	US$‘000	US$‘000	US$‘000
At a point in time	31,949	11,395	43,344
Over time	441	-	441

Total	32,390	11,395	43,785

		Rest of World
Timing of revenue recognition	Americas	Ireland	Total
Year ended December 31, 2024	US$‘000	US$‘000	US$‘000
At a point in time	41,536	19,763	61,299
Over time	256	-	256

Total	41,792	19,763	61,555

		Rest of World
Timing of revenue recognition	Americas	Ireland	Total
Year ended December 31, 2023	US$‘000	US$‘000	US$‘000
At a point in time	44,692	11,848	56,540
Over time	292	-	292

Total	44,984	11,848	56,832

Timing of revenue recognition	Americas	Asia / Africa	Europe	Total
Year ended December 31, 2025	US$‘000	US$‘000	US$‘000	US$‘000
At a point in time	24,182	15,383	3,778	43,343
Over time	442	-	-	442

Total	24,624	15,383	3,778	43,785

Timing of revenue recognition	Americas	Asia / Africa	Europe	Total
Year ended December 31, 2024	US$‘000	US$‘000	US$‘000	US$‘000
At a point in time	29,661	24,775	6,863	61,299
Over time	256	-	-	256

Total	29,917	24,775	6,863	61,555

Timing of revenue recognition	Americas	Asia / Africa	Europe	Total
Year ended December 31, 2023	US$‘000	US$‘000	US$‘000	US$‘000
At a point in time	31,990	18,909	5,641	56,540
Over time	292	-	-	292

Total	32,282	18,909	5,641	56,832

	Rest of World
	Americas	Ireland	Other	Total
Year ended December 31, 2025	US$‘000	US$‘000	US$‘000	US$‘000
Result before transformation costs, impairment and unallocated expenses	(1,291)	(5,639)	(327)	(7,257)
Transformation costs	(1,241)	(3,011)	-	(4,252)
Impairment charges	(2,177)	-	-	(2,177)

Result after impairment	(4,709)	(8,650)	(327)	(13,686)
Unallocated expenses *				(2,103)

Operating loss				(15,789)
Net financing expense (Note 6)				(21,388)

Loss before tax				(37,177)
Income tax charge (Note 7)				(199)

Loss for the year on continuing operations				(37,376)
Loss for the year on discontinued operations (Note 8)				-

Loss for the year				(37,376)

	Rest of World
	Americas	Ireland	Other	Total
Year ended December 31, 2024	US$‘000	US$‘000	US$‘000	US$‘000
Result before transformation costs, impairment and unallocated expenses	(2,503)	(9,386)	(315)	(12,204)
Transformation costs	(2,025)	(2,156)		(4,181)
Impairment charges	(612)	(796)	-	(1,408)

Result after impairment	(5,140)	(12,338)	(315)	(17,793)
Unallocated expenses *				(3,372)

Operating loss				(21,165)
Net financing expense (Note 6)				(9,565)

Loss before tax				(30,730)
Income tax charge (Note 7)				(486)

Loss for the year on continuing operations				(31,216)
Loss for the year on discontinued operations (Note 8)				(573)

Loss for the year				(31,789)

	Rest of World
	Americas	Ireland	Other	Total
Year ended December 31, 2023	US$‘000	US$‘000	US$‘000	US$‘000
Result before transformation costs, impairment and unallocated expenses	(4,365)	(7,886)	(104)	(12,355)
Impairment charges	(11,105)	-	-	(11,105)

Result after impairment	(15,470)	(7,886)	(104)	(23,460)
Unallocated expenses *				(3,585)

Operating loss				(27,045)
Net financing expense (Note 6)				(9,882)

Loss before tax				(36,927)
Income tax credit (Note 7)				59

Loss for the year on continuing operations				(36,868)
Profit for the year on discontinued operations (Note 8)				12,850

Loss for the year				(24,018)

*	Unallocated expenses represent head office general and administration costs of the Group, which cannot be allocated to the results of any specific geographical area.

	Rest of World
	Americas	Ireland	Other	Total
As at December 31, 2025	US$‘000	US$‘000	US$‘000	US$‘000
Assets and liabilities
Segment assets	35,219	60,404	24	95,647
Unallocated assets:
Income tax assets (current and deferred)				4,380
Cash and cash equivalents and short-term investments				5,138

Total assets as reported in the Group balance sheet				105,165

Segment liabilities	129,073	43,033	26	172,132
Unallocated liabilities:
Income tax liabilities (current and deferred)				5,015

Total liabilities as reported in the Group balance sheet				177,147

	Rest of World
	Americas	Ireland	Other	Total
As at December 31, 2024	US$‘000	US$‘000	US$‘000	US$‘000
Assets and liabilities
Segment assets	32,798	61,254	-	94,052
Unallocated assets:
Income tax assets (current and deferred)				4,071
Cash and cash equivalents and short-term investments				5,167

Total assets as reported in the Group balance sheet				103,290

Segment liabilities	84,863	48,621	62	133,546
Unallocated liabilities:
Income tax liabilities (current and deferred)				4,925

Total liabilities as reported in the Group balance sheet				138,471